Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma
Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
Kathryn Kolibaba, MD, hematologist, Compass Oncology, US Oncology Network, discusses results from the phase II trial dubbed Pyramid Trial (NCT00931918). The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL).
Kolibaba says it came as a surprise to researchers that the addition of bortezomib to R-CHOP did not produce a significant outcome. She said despite this, researchers still gathered important information about diagnostic criteria from across the United States that will allow for a quicker accrual for upcoming trials.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
